News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Chronogen Inc. Announces Two Senior Appointments

10/19/2005 5:13:15 PM

MONTREAL, April 12 /PRNewswire/ -- Chronogen Inc., a drug discovery company developing human novel therapeutics to treat age-dependent diseases is pleased to announce two appointments strongly reinforcing its management team: Pierre-Yves Desbiens, CA, MBA, as Vice-President Finance and Administration, and Dr. Pascal Puchois as Vice-President Corporate and Business Development.

Commenting on these appointments, Dr. Max Fehlmann, President and CEO, Chronogen Inc. said:

"These appointments directly result from the strategic focus of our business plan. Both VPs have the key attributes we were looking for: competency and experience that will contribute significantly to the development of Chronogen".

"Pierre-Yves' experience in financing and partnership development will be a tremendous asset to Chronogen, particularly to help meet our financial and strategic growth objectives, said Max Fehlmann. His in-depth knowledge of the biopharmaceutical sector as well as a strong track record in the negotiation and the execution of financial transactions will be valuable to Chronogen".

Mr. Desbiens holds a bachelor's degree in Accounting from the University of Quebec, and a Master's degree in Business Administration with a finance concentration from the Hautes Etudes Commerciales of the University of Montreal. Before joining Chronogen, he was Senior Investment Advisor, Life Sciences, at the Fonds de Solidarite FTQ, the most important venture capital institutional investor, in the life science sector, in Canada. Prior to the Fonds, he was Chief Financial Officer and General Manager of Horizon Sciences & Technologies Inc, an important bio-pharmaceutical company based in Montreal, involved in the research and development of treatment products and diagnostic devices in the field of Osteoarthritis. Before his experience in the Healthcare sector, Mr. Desbiens held different positions in corporate finance, with mid-size to multinational corporation such as, Domtar Inc, Price Waterhouse and Oceanex Inc, where he played a major role in the IPO.

"In Dr. Puchois we found the leadership and expertise in developing partnership opportunities and other strategies in support of the Company's growth plan. Moreover, Dr. Puchois also has a wide knowledge of the drug development from discovery to clinical development mainly in atherosclerosis field. Pascal will play a crucial role in our partnering activities and, importantly, in developing and executing strategies for advancing and expanding our product portfolio for prevention and treatment of cardiovascular diseases and related diseases."

Dr. Puchois is a pharmacist and a clinical chemist. He obtained a Ph.D in Biochemistry and a Ph.D. in Pharmaceutical Sciences. Dr. Puchois began his career as a researcher at Pasteur Institute of Lille then at various research laboratories in the U.S and Europe. His scientific interest was focused on the lipoprotein metabolism and atherosclerosis. Since 1988, Dr. Puchois has created and managed several contract research organizations for which he was also responsible for building the company's business. Prior to joining Celmed in 2003, he was VP Preclinical Research and Technologies at Celmed BioSciences. Immediately prior to joining Celmed, Dr. Puchois was VP worldwide strategy and acting CEO at Bio-Inova Life Sciences International in Montreal.

About Chronogen

Chronogen Inc., a privately-held drug discovery company, is a leader in the identification of targets that control the degenerative processes of aging. Chronogen is a biopharmaceutical company dedicated to the discovery and the development of innovative products for the prevention and treatment of age- related diseases. Based on this innovative approach, the company is developing novel products to control lipid and oxidative stress levels, which are established disease mechanisms in cardiovascular disorders. The control of aging in whole model organisms has provided very valuable assets for a drug discovery technology that will lead to novel and efficacious drugs in significant markets including atherosclerosis, vascular complications of diabetes, and ischemia/reperfusion injuries. Chronogen is headquartered in Montreal, Canada. Further information can be found at .


CONTACT: Max Fehlmann, President & CEO, (514) 521-9595,

Read at

comments powered by Disqus